Novo Nordisk (NYSE: NVO) was featured in a recent analysis report that discussed rocketing mentions of the company’s Ozempic drug (+86). “Ozempic (made by Novo Nordisk) currently holds a massive brand recognition lead when it comes to mention volume vs. other established brand names,” reads the report, written by LikeFolio Founder Andy Swan. The publication also mentions NVO’s peers in the surging space, all “vying for a piece of the weight-loss pie.” “But we wonder, could developments in this segment be a case of a rising tide lifting all boats? Consumer mentions of using a weight-loss drug are accelerating in the current quarter.”
About Novo Nordisk
Novo Nordisk is a global health care company, founded in 1923 and headquartered just outside Copenhagen, Denmark. Its purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity, and rare blood and rare endocrine diseases. Novo Nordisk does so by pioneering scientific breakthroughs, expanding access to its medicines and working to prevent and ultimately cure the diseases it treats. Novo Nordisk employs more than 55,000 people in 80 offices around the world and markets its products in 170 countries.
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork